Cargando…
Metformin Targets Foxo1 to Control Glucose Homeostasis
Metformin is the first-line pharmacotherapy for type 2 diabetes mellitus (T2D). Metformin exerts its glucose-lowering effect primarily through decreasing hepatic glucose production (HGP). However, the precise molecular mechanisms of metformin remain unclear due to supra-pharmacological concentration...
Autores principales: | Guo, Xiaoqin, Li, Xiaopeng, Yang, Wanbao, Liao, Wang, Shen, James Zheng, Ai, Weiqi, Pan, Quan, Sun, Yuxiang, Zhang, Kebin, Zhang, Rui, Qiu, Yuyang, Dai, Qian, Zheng, Hongting, Guo, Shaodong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8231152/ https://www.ncbi.nlm.nih.gov/pubmed/34208360 http://dx.doi.org/10.3390/biom11060873 |
Ejemplares similares
-
Suppression of FOXO1 attenuates inflamm‐aging and improves liver function during aging
por: Yang, Wanbao, et al.
Publicado: (2023) -
Hepatocyte FoxO1 Deficiency Protects From Liver Fibrosis via Reducing Inflammation and TGF-β1-mediated HSC Activation
por: Pan, Quan, et al.
Publicado: (2023) -
Regulation of Macronutrients in Insulin Resistance and Glucose Homeostasis during Type 2 Diabetes Mellitus
por: Yang, Wanbao, et al.
Publicado: (2023) -
Alteration of gut microbiota induced by DPP-4i treatment improves glucose homeostasis
por: Liao, Xiaoyu, et al.
Publicado: (2019) -
Metformin inhibits hepatocellular carcinoma development by inducing apoptosis and pyroptosis through regulating FOXO3
por: Shen, Zetian, et al.
Publicado: (2021)